Sham injection

Pegaptanib 0.3 mg is administered as an intravitreous injection every 6 weeks. In clinical studies, patients treated with pegaptanib experienced a slower rate of visual decline than patients treated with a sham injection.28 Vision loss continued to occur in patients and the drug was less effective in the second year of treatment. Long-term efficacy studies are not available yet.27... 

The largest randomized trial to date was performed by Gillies et al. (49). This study was a randomized, double-masked, placebo-controlled trial of triamcinolone acetonide intravitreal injection in patients with classic CNV associated with AMD. Patients were randomized to receive a single injection of triamcinolone acetonide, 4mg (n = 75) or to receive a sham injection (n = 76). At 12 months the risk of severe visual loss (30 letters) was 35% for both the treated group and the placebo group. Although the visual acuity did not differ between the treated and control groups, at three months, the choroidal neovascular complex appeared to be smaller in the... 

A total of 1186 patients were included in efficacy analyses 7545 intravitreous injections of pegaptanib sodium and 2557 sham injections were administered. Approximately 90% of the patients in each treatment group completed the study. An average of 8.5 injections were administered per patient out of a possible total of nine injections. 

The PIER trial was a Phase IIIB trial in which AMD patients with subfoveal minimally classic, predominantly classic, or occult-only CNV were randomized 1 1 1 to receive 300 or 500 pg of ranibizumab or a sham injection. Three monthly injections were followed by injections every three months thereafter. 

Figure 1 Neither anti-IgE nor mast cell deficiency alters BAL cellular composition. N as per Table 1. Mast cell-deficient (W/Wv) mice and wild-type control mice (WT) were sham injected or sensitized with 10 (xg ovalbumin (OVA) IP and 0.75 mg of ALUM on day 0. Starting on day 14 through day 21, all mice received a 30-minute inhalation challenge of aerosolized 1% OVA delivered by a DeVilbiss ultrasonic nebulizer. Antibody-pretreated mice were injected (200 (xg sc) with anti-IgE or an isotype control antibody on days -21, — 14, —1, 0, 7, 14, and 18. On days 14 through 21, mice also received daily inhalations of anti-IgE or control antibody (12 mg aerosolized to completion, deposited lung dose 2 Xg/mouse). Inhalation anti-IgE treatment occurred 1 hour prior to OVA inhalation challenge, p < 0.0001 for overall difference between groups by ANOVA. Only differences between nonsensitized and sensitized groups different by subtest (p < 0.0001). Data are mean standard deviation. PMN, polymorphonuclear leukocyte.

Moreover, the hyperactivity seen in the sham rats was somewhat greater than that usually observed following this dose of AMPH, suggesting a cross-sensitization between MDMA and AMPH. The day after the AMPH injections, all the rats were reinjected with saline. At this time there was no significant difference between the sham- and lesion-operated rats. 

Biochemical analyses of 6-OHDA-injected animals revealed a 93 percent depletion of dopamine. The tissue was assayed using electrochemical detection following separation by high-pressure liquid chromatography (Felice et al. 1978). recorded as ng/mg protein in the nucleus accumbens and compared to control rats with sham lesions (sham=65.5 4.4, lesion=4.9 1.5 t(39)=23.4). A lesion was defined as complete if 75 percent or more of the dopamine was determined to be depleted from the nucleus accumbens compared to mean sham group values. 

One of the factors that influence the magnitude of the placebo effect is the way in which the placebo is administered. Placebo injections, for example, are more effective than placebo pills and placebo acupuncture - which uses sham needles that retract into their handles like the blade of a stage dagger, rather than piercing the skin - is also more effective than placebo pills.19 The most powerful placebo of all is surgery. Approximately 45 per cent of patients with Parkinson s disease get better when treated with sham surgery, but only 14 per cent of Parkinson s disease patients improve when treated with placebo pills.20... 

Fig. 7. Effects of L-PDMP on spatial cognition deficit induced by repeated cerebral ischemia. (A) Protocol for behavioral experiments to evaluate the efficacy of L-PDMP against spatial cognition deficit in rats with cerebral ischemia. (B) Sham (sham-operated rats, n — 11), Group 1-vehicle, l-PDMP (i.p. injections of vehicle or 40 mg/kg L-PDMP twice a day for 6 days from 24 h after ischemia, n = 13), Group 2-vehicle, L-PDMP (i.p. injection of vehicle or 40 mg/kg L-PDMP twice a day for 4 days from 3 days after ischemia, n — 9 and n — 10, respectively). P < 0.001 versus sham-operated rats, P < 0.05 and P < 0.01 versus vehicle-treated rats (Wilcoxon s rank sum test).

In another experiment, TAG was removed from virgin ligated females 1 hour before the 3rd scotophase. Three hours after surgery, females were injected with 10 pmol of PBAN in 20 Hi sucrose-phosphate buffer. Sham operated females were used as controls. Pheromone was extracted after 3 hours. There was no significant difference in... 

Note that gastrin injection produced the maximal rate of add output, followed by sham feeding and by talking about food. If the latter responses are lo be calculated as percentages of this maximum, the basal rate most be subtracted from all three values first. This manipulation is a simple example of the preliminary corrections that must be applied to experimental data before more complicated questions can be answered correctly. 

---